- Review
Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade
- Maria Vanessa Perez-Gomez,
- Maria Dolores Sanchez-Niño,
- Ana Belen Sanz,
- Catalina Martín-Cleary,
- Marta Ruiz-Ortega,
- Jesus Egido,
- Juan F. Navarro-González,
- Alberto Ortiz and
- Beatriz Fernandez-Fernandez
Diabetic kidney disease is the most frequent cause of end-stage renal disease. This implies failure of current therapeutic approaches based on renin-angiotensin system (RAS) blockade. Recent phase 3 clinical trials of paricalcitol in early diabetic k...

